3期IDEAL研究积极结果进一步支持Livdelzi®(Seladelpar)在广泛原发性胆汁性胆管炎(PBC)患者群体二线治疗中助力实现ALP正常化目标

美股速递
Nov 05

3期IDEAL研究积极结果进一步支持Livdelzi®(Seladelpar)在广泛原发性胆汁性胆管炎(PBC)患者群体二线治疗中助力实现ALP正常化目标

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10